2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke

Po-Sheng Chen; Meng Lee; Sung-Chun Tang; Po-Hsun Huang; Hung-I Yeh; Charles Jia-Yin Hou; I-Chang Hsieh; Jiunn-Tay Lee; Jiann-Shing Jeng; Yi-Heng Li

doi:10.1016/j.jfma.2022.03.001

2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke

J Formos Med Assoc. 2022 Aug;121(8):1363-1370. doi: 10.1016/j.jfma.2022.03.001. Epub 2022 Apr 8.

Authors

Po-Sheng Chen¹, Meng Lee², Sung-Chun Tang³, Po-Hsun Huang⁴, Hung-I Yeh⁵, Charles Jia-Yin Hou⁶, I-Chang Hsieh⁷, Jiunn-Tay Lee⁸, Jiann-Shing Jeng⁹, Yi-Heng Li¹⁰

Affiliations

¹ Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
² Department of Neurology, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi, Taiwan.
³ Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁵ Departments of Internal Medicine and Medical Research, MacKay Memorial Hospital, Taipei, Taiwan; Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
⁶ Cardiovascular Center, MacKay Memorial Hospital, Taipei, Taiwan.
⁷ Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
⁸ Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan.
⁹ Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: jsjeng@ntu.edu.tw.
¹⁰ Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: heng@mail.ncku.edu.tw.

PMID: 35410823
DOI: 10.1016/j.jfma.2022.03.001

Abstract

The previously published 2017 Taiwan Lipid Guidelines for High Risk Patients becomes the standard guidance of dyslipidemia management for patients with atherosclerotic cardiovascular disease (ASCVD) in Taiwan. New clinical trials of lipid lowering therapy were published successively after 2017. The study results changed the treatment concept of ASCVD. Therefore, an update focusing on the lipid treatment strategy for patients with ASCVD becomes necessary. In this focused update of the 2017 guideline, the treatment targets of low-density lipoprotein cholesterol (LDL-C) for patients with ASCVD were modified. The algorithm of LDL-C lowering therapy was revised. The recommendations in this focused update were made mainly based on the scientific evidence from recently published clinical trials and endorsed by the major medical societies in Taiwan.

Keywords: Atherosclerotic cardiovascular disease; Guidelines; Hyperlipidemia; Taiwan.

Publication types

Practice Guideline

MeSH terms

Arteries
Atherosclerosis*
Cardiovascular Diseases*
Cholesterol, LDL
Coronary Artery Disease* / drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Ischemic Stroke*
Peripheral Arterial Disease* / therapy
Taiwan

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors